Literature DB >> 3007172

Cyclic GMP as the mediator of molsidomine-induced vasodilatation.

W R Kukovetz, S Holzmann.   

Abstract

The mode of action of the in vitro active metabolites SIN-1 and SIN-1A of the vasodilator prodrug molsidomine was studied in bovine coronary artery strips. Both compounds increased cyclic GMP levels in close association with, but prior to their relaxing action. Relaxation and rises in cyclic GMP by SIN-1 were potentiated by M & B 22,948, an inhibitor of cyclic GMP phosphodiesterase and attenuated by methylene blue, a dye that inhibits activation of guanylate cyclase by SIN-1 and various nitrovasodilators. A single significant correlation between rises in cGMP and relaxation was obtained for both SIN compounds and various nitrovasodilators. Relaxation by SIN-1A was independent of the presence of endothelium and was not affected by various inhibitors of arachidonic acid metabolism. In contrast to nitroglycerin, SIN-1 did not induce substantial tolerance nor were its actions reduced in artery strips that were tolerant to nitroglycerin. The results indicate that SIN-1A relaxes coronary smooth muscle by a direct stimulant effect on soluble guanylate cyclase in vascular smooth muscle cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3007172     DOI: 10.1016/0014-2999(86)90164-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

1.  Endothelium- and sydnonimine-induced responses of native and cultured aortic smooth muscle cells are not impaired by nitroglycerin tolerance.

Authors:  A Mülsch; R Busse; I Winter; E Bassenge
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-05       Impact factor: 3.000

2.  The effects of the nitric oxide donor molsidomine prevent in warm ischemia-reperfusion injury of the rat renal--a functional and histophatological study.

Authors:  H Oztürk; M Aldemir; H Büyükbayram; A I Dokucu; S Otçu
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

3.  Prophylactic administration of L-arginine improves the intestinal barrier function after mesenteric ischaemia.

Authors:  R Schleiffer; F Raul
Journal:  Gut       Date:  1996-08       Impact factor: 23.059

4.  Protective and therapeutic effect of molsidomine on bleomycin-induced lung fibrosis in rats.

Authors:  Talat Kilic; Hakan Parlakpinar; Alaadin Polat; Elif Taslidere; Nigar Vardi; Ediz Sarihan; Hilal Ermis; Kevser Tanbag
Journal:  Inflammation       Date:  2014-08       Impact factor: 4.092

5.  The effects of molsidomine on hypoxia inducible factor alpha and Sonic hedgehog in testicular ischemia/reperfusion injury in rats.

Authors:  Ali Ihsan Dokucu; Hulya Ozturk; Hayrettin Ozturk; Mehmet Cudi Tuncer; Fahri Yilmaz
Journal:  Int Urol Nephrol       Date:  2008-09-12       Impact factor: 2.370

6.  Role of the L-arginine-NO pathway and of cyclic GMP in electrical field-induced noradrenaline release and vasoconstriction in the rat tail artery.

Authors:  B Bucher; S Ouedraogo; M Tschöpl; D Paya; J C Stoclet
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

7.  The nitric oxide donor molsidomine prevents ischemia/reperfusion injury of the adult rat small intestine.

Authors:  Hayrettin Oztürk; Mustafa Aldemir; Ali Ihsan Dokucu; Yusuf Yağmur; Nihal Kilinç; Ahmet Hikmet Sahin
Journal:  Pediatr Surg Int       Date:  2003-06-03       Impact factor: 1.827

8.  The protective role of molsidomine on the Cisplatin-induced ototoxicity.

Authors:  Yuksel Toplu; Hakan Parlakpinar; Emrah Sapmaz; Erkan Karatas; Alaattin Polat; Ahmet Kizilay
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2014-04-02

9.  Effect of nitrate tolerance and dipyridamole on the response to SIN1 in the human isolated saphenous vein.

Authors:  M Bohyn; G Berkenboom; J Fontaine
Journal:  Cardiovasc Drugs Ther       Date:  1991-04       Impact factor: 3.727

10.  Cytoprotective effects of molsidomine against methotrexate-induced hepatotoxicity: an experimental rat study.

Authors:  Emine Turkmen Samdanci; Mustafa Huz; Onural Ozhan; Kevser Tanbek; Esra Pamukcu; Ayse Nur Akatli; Hakan Parlakpinar
Journal:  Drug Des Devel Ther       Date:  2018-12-20       Impact factor: 4.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.